Editorial: does anti‐TNF ‘treatment persistence’ always equate to ‘effective treatment’? Only objective disease assessments can answer the question. Authors' reply-Reference-Cited by-同舟云学术

Editorial: does anti‐TNF ‘treatment persistence’ always equate to ‘effective treatment’? Only objective disease assessments can answer the question. Authors' reply

Published:2021-08-11 Issue:5 Volume:54 Page:720-721
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Blesl Andreas¹^ORCID,Högenauer Christoph¹²^ORCID,Borenich Andrea³,Berghold Andrea³,Wenzl Heimo¹,Petritsch Wolfgang¹

Affiliation:

1. Division of Gastroenterology and Hepatology Department of Internal Medicine Medical University of Graz Graz Austria

2. Biotechmed Graz Austria

3. Institute for Medical Informatics, Statistics and Documentation Medical University of Graz Graz Austria

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16535

Reference7 articles.

1. Editorial: does anti‐TNF ‘treatment persistence’ always equate to ‘effective treatment’? Only objective disease assessments can answer the question;Srinivasan A;Aliment Pharmacol Ther,2021

2. Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: results from a 20‐year real‐world study;Blesl A;Aliment Pharmacol Ther,2021

3. The risk of relapse after anti‐TNF discontinuation in inflammatory bowel disease: systematic review and meta‐analysis;Gisbert JP;Am J Gastroenterol,2016

4. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune‐mediated inflammatory diseases: a randomized clinical trial;Syversen SW;JAMA,2021

5. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease;Fernandes SR;Inflamm Bowel Dis,2020